GSTP1与晚期非小细胞肺癌含铂类药物近期疗效的关系

目的:探讨GSTP1与接受含铂方案化疗的晚期非小细胞肺癌患者的近期治疗的关系。方法:经病理确诊的晚期非小细胞肺癌患者62例,接受含铂方案化疗至少2周期后评价疗效,采用TaqMan探针实时荧光定量聚合酶链反应(PCR)法和直接测序法对患者外周血GSTP1第105位密码子进行多态性分析,分析各基因型与晚期非小细胞肺癌患者近期疗效的相关性。结果:携带至少一个Val基因的患者的疗效大于携带Ile/Ile基因的患者(45%VS 28.6%,OR=0.25,95%CI=0.062 2～0.954;P<0.05)。结论:GSTP1 105多态性与NSCLC患者对铂类药物化疗的敏感性相关。

The Relationship of GSTP1 and Clinical Response to Platinum Based Chemotherapy in Advanced Non-small Cell Lung Cancer

Objective:To study the relationship of GSTP1 and clinical response response to platinum based chemotherapy in advanced non-small cell lung cancer(NSCLC).Methods:A total of 62 patients with advanced NSCLC were routinely treated by cisplatin or carboplatin-based chemotherapy.The clinical response was evaluated after at least 2 cycles.Single nuclear polymorphisms(SNPs) in GSTP1 IIe105Val were assessed with 5'nuclease allelic discrimination assay(TaqMan) by real-time polymerase chain reaction and direct sequencing.The genotypes were tested for an association with clinical response response in platin-based chemotherapy in advanced NSCLC.Results:The response rate to chemotherapy was significantly higher in patients with the Ile/Val +Val/Val genotype than in patient with Ile/Ile genotype(45% VS 28.6%,OR=0.25,95% CI= 0.062 2～0.954;P<0.05).Conclusion:Polymorphisms in the GSTP1 105 may have significant impact on the response of NSCLC patients platin-based chemotherapy.